Cyclophosphamide Injection

Risk for myelosuppression, immunosuppression, bone marrow failure, infections. Monitor CBCs during treatment. Do not initiate therapy if neutrophils ≤1,500/mm³ and platelets <50,000/mm³. Interrupt or reduce dose if serious infection occurs; consider using G-CSF to reduce risk. Increased risk for severe myelosuppression if pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy. Exclude or correct any urinary tract obstructions prior to initiation; check urinary sediment regularly for signs of urotoxicity and/or nephrotoxicity. Active urinary tract infections. Monitor in patients with risk factors for cardiotoxicity and with pre-existing cardiac disease. Monitor for pulmonary toxicity. May interfere with wound healing. May contain alcohol. Severe renal or hepatic impairment: monitor. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for up to 1 year (females of reproductive potential) and for 4 months (males w. female partners) after completion of therapy. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).

Risk for myelosuppression, immunosuppression, bone marrow failure, infections. Monitor CBCs during treatment. Do not initiate therapy if neutrophils ≤1,500/mm³ and platelets <50,000/mm³. Interrupt or reduce dose if serious infection occurs; consider using G-CSF to reduce risk. Increased risk for severe myelosuppression if pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy. Exclude or correct any urinary tract obstructions prior to initiation; check urinary sediment regularly for signs of urotoxicity and/or nephrotoxicity. Active urinary tract infections. Monitor in patients with risk factors for cardiotoxicity and with pre-existing cardiac disease. Monitor for pulmonary toxicity. May interfere with wound healing. May contain alcohol. Severe renal or hepatic impairment: monitor. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for up to 1 year (females of reproductive potential) and for 4 months (males w. female partners) after completion of therapy. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).

Risk for myelosuppression, immunosuppression, bone marrow failure, infections. Monitor CBCs during treatment. Do not initiate therapy if neutrophils ≤1,500/mm³ and platelets <50,000/mm³. Interrupt or reduce dose if serious infection occurs; consider using G-CSF to reduce risk. Increased risk for severe myelosuppression if pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy. Exclude or correct any urinary tract obstructions prior to initiation; check urinary sediment regularly for signs of urotoxicity and/or nephrotoxicity. Active urinary tract infections. Monitor in patients with risk factors for cardiotoxicity and with pre-existing cardiac disease. Monitor for pulmonary toxicity. May interfere with wound healing. May contain alcohol. Severe renal or hepatic impairment: monitor. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for up to 1 year (females of reproductive potential) and for 4 months (males w. female partners) after completion of therapy. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).

Risk for myelosuppression, immunosuppression, bone marrow failure, infections. Monitor CBCs during treatment. Do not initiate therapy if neutrophils ≤1,500/mm³ and platelets <50,000/mm³. Interrupt or reduce dose if serious infection occurs; consider using G-CSF to reduce risk. Increased risk for severe myelosuppression if pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy. Exclude or correct any urinary tract obstructions prior to initiation; check urinary sediment regularly for signs of urotoxicity and/or nephrotoxicity. Active urinary tract infections. Monitor in patients with risk factors for cardiotoxicity and with pre-existing cardiac disease. Monitor for pulmonary toxicity. May interfere with wound healing. May contain alcohol. Severe renal or hepatic impairment: monitor. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for up to 1 year (females of reproductive potential) and for 4 months (males w. female partners) after completion of therapy. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).

Risk for myelosuppression, immunosuppression, bone marrow failure, infections. Monitor CBCs during treatment. Do not initiate therapy if neutrophils ≤1,500/mm³ and platelets <50,000/mm³. Interrupt or reduce dose if serious infection occurs; consider using G-CSF to reduce risk. Increased risk for severe myelosuppression if pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy. Exclude or correct any urinary tract obstructions prior to initiation; check urinary sediment regularly for signs of urotoxicity and/or nephrotoxicity. Active urinary tract infections. Monitor in patients with risk factors for cardiotoxicity and with pre-existing cardiac disease. Monitor for pulmonary toxicity. May interfere with wound healing. May contain alcohol. Severe renal or hepatic impairment: monitor. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for up to 1 year (females of reproductive potential) and for 4 months (males w. female partners) after completion of therapy. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).